# Deep Medicine

> AI-powered early diagnostics for neurodegenerative diseases. AI-powered, non-invasive early detection for neurodegenerative disease, designed to surface risk up to a decade before symptoms appear.

## Key facts
- Company: Deep Medicine BV, Beveren, Belgium. Founded 2018.
- What it is: a smartphone-based platform that captures five digital biomarker streams in one session (voice, eye tracking, facial expression, equilibrium, neurocognitive performance) and fuses them into a neurocognitive risk score for a prescribing specialist.
- Status today: CE Class I certified; five biomarker streams live; peer-reviewed scientific basis; hospital and academic partners; seven years of R&D.
- Objectives (forward-looking, not yet achieved): CE Class IIa upgrade, a 3,000-patient clinical trial, DiGA and PECAN reimbursement, a screening episode under EUR 100, commercial launch in Belgium and the Netherlands targeted for Q4 2027.
- Contact: https://deepmedicine.io/contact (web form)

## Overview
Most neurodegenerative disease is diagnosed once damage is already advanced, through invasive, slow and expensive pathways. Deep Medicine reads the earliest digital biomarkers non-invasively, so neurocognitive change can be seen far earlier and at a cost designed for population-scale screening.

## What makes it different
- Non-invasive: no blood draw, no scanner, no clinic visit. A session runs on a standard smartphone.
- Multi-modal: five biomarker streams read together, not one signal in isolation.
- Evidence-led: each stream rests on peer-reviewed literature, validated with hospital and academic partners.
- Compounding data: the platform is designed to sharpen with every additional session under clinical validation.

## Products
- Deep Diagnose (capture): five biomarker streams in one session; a risk score and specialist report for the prescribing clinician.
- Deep Therapy (act): daily neurotraining for monitoring and self-management, with periodic specialist review.

## Science and evidence
Biomarker streams: voice and speech, eye tracking and saccadics, neurocognitive performance, facial expression, each grounded in peer-reviewed literature. A 3,000-patient trial is designed across three cohorts and four hospital sites to support the full EU regulatory file; pre-registration on ClinicalTrials.gov is planned. The trial is a forward-looking objective, not a completed result.

## Company
Leadership: James Troch (CEO), Tom De Bast (CFO). A team of data and medical scientists, with an advisory board of senior academic neurologists across Belgium, Luxembourg and Germany.

## Site structure
- https://deepmedicine.io/the-challenge
- https://deepmedicine.io/diagnostics-and-therapy
- https://deepmedicine.io/our-approach
- https://deepmedicine.io/science-and-evidence
- https://deepmedicine.io/technology
- https://deepmedicine.io/company
- https://deepmedicine.io/for-investors
- https://deepmedicine.io/trust-and-compliance
- https://deepmedicine.io/contact
- https://deepmedicine.io/news

## Recent news
- What your eyes give away before your memory does. (2026-06-20): https://deepmedicine.io/news/eye-movements-early-alzheimers-parkinsons — Eye movements change in early Alzheimer’s and Parkinson’s, often before memory does. What saccade research shows, and why a camera can now capture it.
- Balance can be one of Parkinson’s earliest tells. (2026-06-19): https://deepmedicine.io/news/balance-gait-early-parkinsons-biomarker — Changes in balance and gait can appear before a Parkinson’s diagnosis. Sensor research shows these early motor signals are measurable and increasingly portable.
- The 170 billion euro problem behind early detection (2026-06-18): https://deepmedicine.io/news/cost-of-dementia-europe — Neurodegenerative disease already costs Europe 170 billion euro a year, and most of it lands on families. Detection timing is part of that cost.
- The face can register change before a person feels it. (2026-06-15): https://deepmedicine.io/news/facial-expression-biomarker-dementia-parkinsons — Facial expression changes in Parkinson’s and dementia are easy to miss. Research suggests a camera can read these subtle shifts as a non-invasive biomarker.
- Why one biomarker is never enough in neurodegeneration. (2026-06-13): https://deepmedicine.io/news/why-one-biomarker-not-enough-neurodegeneration — Neurodegenerative disease affects many systems at once, so single-signal tests miss things. Why research points to combining biomarkers for an earlier picture.